|
Tuesday, December 10, 2024, 7:15 PM – 8:45 PM CT (8:15 PM – 9:45 PM ET) | San Antonio, Texas
Rounds with the Investigators: Compelling Teaching Cases Focused on the Management of HER2-Low and HER2-Ultralow Breast CancerPart 1 of a 3-Part CME Satellite Symposium Series in Partnership with the 2024 San Antonio Breast Cancer Symposium®
Location
San Antonio Marriott Rivercenter 101 Bowie St San Antonio, Texas Hotel Phone: (210) 223-1000 Program Schedule — Central Time 7:15 PM – 8:45 PM — Educational Dinner Meeting Registration and buffet will open at 7:00 PM CT. Meeting Room Grand Ballroom G-M (Third Floor) This event will also be webcast live. Please see Registration tab for details. Faculty
Aditya Bardia, MD, MPH Professor of Medicine Geffen School of Medicine at UCLA Director, Breast Oncology Program Assistant Chief (Translational Research) Division of Medical Oncology Director of Translational Research Integration UCLA Health Jonsson Comprehensive Cancer Center Los Angeles, California Professor Giuseppe Curigliano, MD, PhD Clinical Director Division of Early Drug Development for Innovative Therapy Co-Chair, Cancer Experimental Therapeutics Program Department of Oncology and Hemato-Oncology University of Milano European Institute of Oncology Milano, Italy Hope S Rugo, MD Professor of Medicine Winterhof Family Professor of Breast Cancer Director, Breast Oncology and Clinical Trials Education Medical Director, Cancer Infusion Services University of California, San Francisco Helen Diller Family Comprehensive Cancer Center San Francisco, California Antonio C Wolff, MD, FACP, FASCO Professor of Oncology Johns Hopkins University Baltimore, Maryland Moderator Neil Love, MD Research To Practice Miami, Florida This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Daiichi Sankyo Inc. This is not an official program of the San Antonio Breast Cancer Symposium®.
Program Schedule — Central Time 7:15 PM – 8:45 PM — Educational Dinner Meeting Registration and buffet will open at 7:00 PM CT. MODULE 1: Optimizing the Identification of HER2-Low and HER2-Ultralow Breast Cancer
MODULE 2: Available Data with HER2-Targeted Therapy for HER2-Low and HER2-Ultralow Disease
MODULE 3: Practical Application of HER2-Targeted Therapy for HER2-Low and HER2-Ultralow mBC
MODULE 4: Future Directions for HER2-Targeted Therapy for HER2-Low Breast Cancer
Target Audience
CME Credit Form FACULTY — Dr Wolff has no relevant conflicts of interest to disclose. The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process: Dr Bardia — Consulting Agreements and Contracted Research: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Menarini Group, Merck, Novartis, Pfizer Inc, Sanofi. Professor Curigliano — Advisory Committees and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Bristol Myers Squibb, Daiichi Sankyo Inc, Lilly, Menarini Group, Merck, Novartis, Seagen Inc; Contracted Research: Merck; Data and Safety Monitoring Board/Committee: Roche Laboratories Inc; Scientific Board: Ellipses Pharma; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Lilly, Merck, Novartis, Pfizer Inc. Dr Rugo — Consulting Agreements: Chugai Pharmaceutical Co Ltd, Napo Pharmaceuticals Inc, Puma Biotechnology Inc, Sanofi, Viatris; Contracted Research: Ambrx, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, F Hoffmann-La Roche Ltd, Genentech, a member of the Roche Group, Gilead Sciences Inc, Greenwich LifeSciences Inc, Lilly, Merck, Novartis, OBI Pharma Inc, Pfizer Inc, Stemline Therapeutics Inc. MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd,BeyondSpring Pharmaceuticals Inc, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSeraTherapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Daiichi Sankyo Inc. San Antonio Marriott Rivercenter
This activity is intended for medical oncologists, breast surgeons, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.
There is no fee to participate in this hybrid event. In order to attend the in-person symposium in San Antonio, you must also be registered to attend the 2024 San Antonio Breast Cancer Symposium®. IN-PERSON Registration for clinicians in practice/healthcare professionals
I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer. IN-PERSON Registrationfor clinicians » IN-PERSON Registration for other/industry professionals*
Please note, a limited number of seats are available to other/industry professionals on a first come, first served basis. IN-PERSON Registrationfor nonclinicians »
* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
LIVE WEBCAST Registration for all professionals
Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions. REGISTRATION FOR WEBCAST »Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings. Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153. If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153. |